EC
RVNC

Elequin Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Elequin Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17
Closed -$88 – 649
2024
Q3 		$88 Buy
+17
New +$84 ﹤0.01% 364
2024
Q2 		– Sell
-33
Closed -$162 – 380
2024
Q1 		$162 Sell
33
-29
-47% -$172 ﹤0.01% 225
2023
Q4 		$545 Buy
62
+46
+288% +$377 ﹤0.01% 321
2023
Q3 		$184 Sell
16
-248
-94% -$4.77K ﹤0.01% 365
2023
Q2 		$6.68K Buy
+264
New +$8.22K ﹤0.01% 341
2022
Q3 		– Sell
-50
Closed -$1K – 700
2022
Q2 		$1K Sell
50
-9
-15% -$139 ﹤0.01% 388
2022
Q1 		$1K Buy
+59
New +$895 ﹤0.01% 311

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Elequin Capital's RVNC Position: Q4 2024 in Review

Elequin Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 17 shares — an estimated $88 sold.

Elequin Capital first reported a position in RVNC in Q1 2022 and held it in 7 quarters. The position peaked at $6.68K in Q2 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Elequin Capital reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Elequin Capital sold 17 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $88.
  • Elequin Capital first reported a position in Revance Therapeutics, Inc. in Q1 2022 and held it in 7 quarters.
  • Elequin Capital's Revance Therapeutics, Inc. position peaked at $6.68K in Q2 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Elequin Capital's 13F filing for Q4 2024, filed 18 Feb 2025.